Efficacy of Prebiotics, Probiotics, and Synbiotics in Irritable Bowel Syndrome and Chronic Idiopathic Constipation: Systematic Review and Meta-analysis

Ford, Alexander C; Quigley, Eamonn Martin; Lacy, Brian E.; Lembo, Anthony; Saito, Yuri; Schiller, Lawrence R.; Soffer, Edy E.; Spiegel, Brennan M.; Martin, Paul

doi:10.1038/ajg.2014.202

Cited by 647 publications

(507 citation statements)

References 64 publications

Supporting

Mentioning

438

Contrasting

Unclassified

Order By: Relevance

“…To give a few examples, effects were documented and supported by meta-analysis in antibiotics-associated diarrhea [118], gastroenteritis [119,120], irritable bowel syndrome (IBS) and gut comfort [121], lactose digestion [122], IBD (UC and pouchitis) [123], Clostridium difficile diarrhea (single RCTs) [124].…”

Section: Probiotics Of First Generationmentioning

confidence: 99%

The human gut microbiome as source of innovation for health: Which physiological and therapeutic outcomes could we expect?

2017

View full text Add to dashboard Cite

Summary From the moment of birth, each human being builds a microbe-host symbiosis which is key for the preservation of its health and well-being. This personal symbiotic coexistence is the result of progressive enrichments in microorganism diversity through external supplies. This diversity is nowadays massively overthrown by drastic changes related to clinical practice in birth management, environmental exposure, nutrition and healthcare behaviors. The last two generations have been the frame of massive modifications in life and food habits, with people being more and more sedentary, overfed and permeated with drugs and pollutants. We are now able to measure the impact of these changes on the gut microbiota diversity. Concomitantly, these modifications of lifestyle were associated with a dramatic increase in incidence of immune-mediated diseases including metabolic, allergic and inflammatory diseases and most likely neurodegenerative and psychiatric disorders. Microbiota is becoming a hot topic in the scientific community and in the mainstream media. The number of scientific publications increased by up to a factor three over the last five years, with gastrointestinal and metabolic diseases being the most productive areas. In the intellectual property landscape, the patent families on microbiota have more than doubled in the meantime. In parallel, funding either from National Institutes (e.g. from NIH which funds research mainly in the field of allergies, infections, cancer and cardiovascular diseases, from the White House which launched the national microbiome initiative) or by pharmaceutical companies follow the same trend, showing a boost and a strong support in the research field on microbiota. All major health players are investing in microbiome research as shown by the number of deals signed and by funding during 2015. The Giens round table addressed how the medicine of tomorrow, considering human beings as a human-microbe symbiotic supraorganism, could leverage microbiome knowledge and tools. The rationale for our working group has been structured around four domains of innovation that could derive from ongoing efforts in deciphering the interactions between human cells and intestinal microbiome as a central component of human health, namely: (1) development of stratification and monitoring tools; (2) identification of new target and drug discovery, as a part of our supra-genome; (4) exploitation of microbiota as a therapeutic target that can be modulated; (4) and finally as a source of live biotherapeutics and adjuvants. These four streams will exemplify how microbiota has changed the way we consider a wide range of chronic and incurable diseases and the consequences of long-lasting dysbiosis. In-depth microbiota analysis is opening one of the broadest fields of investigation for improving human and animal health and will be a source of major therapeutic innovations for tackling today's medical unmet needs. We thus propose a range of recommendations for basic researchers, care givers as well as for hea...

show abstract

Section: Probiotics Of First Generationmentioning

confidence: 99%

The human gut microbiome as source of innovation for health: Which physiological and therapeutic outcomes could we expect?

2017

View full text Add to dashboard Cite

show abstract

“…2 Although there is some evidence form RCTs for the efficacy of probiotics in the treatment of IBS, 3 which organisms, species, and strains are beneficial remains unclear. 4 More data are therefore welcome, and the authors should be commended for their study, in which they assessed the efficacy of Saccharomyces cerevisiae (SC) compared with placebo.…”

Section: Word Count: 279mentioning

confidence: 99%

Comment on “A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome” by Guillaume Pineton de Chambrun et al. [Digestive and Liver Disease 2015;47:119–24]

Quinn

Ford

2015

Digestive and Liver Disease

View full text Add to dashboard Cite

“…38 The exact mechanism of action, optimal regimen and delivery mode, and durability of efficacy remains to be determined. Moreover, although adverse events with probiotics are rare, there are little long-term safety data available.…”

Section: Rome III Rome Ivmentioning

confidence: 99%

“…Moreover, although adverse events with probiotics are rare, there are little long-term safety data available. 38 Finally, the efficacy of different probiotic strains is variable and limits their use as a first-line treatment. 38 Statement 22: Short-term rifaximin has been found to be effective in relieving bloating symptoms.…”

Section: Rome III Rome Ivmentioning

confidence: 99%

The current treatment landscape of irritable bowel syndrome in adults in Hong Kong: consensus statements

Chan

et al. 2017

Hong Kong Med J

View full text Add to dashboard Cite

Efficacy of Prebiotics, Probiotics, and Synbiotics in Irritable Bowel Syndrome and Chronic Idiopathic Constipation: Systematic Review and Meta-analysis

Abstract: Probiotics are effective treatments for IBS, although which individual species and strains are the most beneficial remains unclear. Further evidence is required before the role of prebiotics or synbiotics in IBS is known. The efficacy of all three therapies in CIC is also uncertain.

Cited by 647 publications

References 64 publications

The human gut microbiome as source of innovation for health: Which physiological and therapeutic outcomes could we expect?

The human gut microbiome as source of innovation for health: Which physiological and therapeutic outcomes could we expect?

Comment on “A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome” by Guillaume Pineton de Chambrun et al. [Digestive and Liver Disease 2015;47:119–24]

The current treatment landscape of irritable bowel syndrome in adults in Hong Kong: consensus statements

Contact Info

Product

Resources

About